MENU
Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Nov 05, 2023

Week's Success: Trader Robot Nets +5.60% Increase for $LGVN

Recently, the "Trend Trader, Popular Stocks: Price Action Trading Strategy (TA&FA)" AI trading bots showcased their capabilities, resulting in a commendable +5.60% gain while trading LGVN over the previous week. Let's delve deeper into this performance and understand the context within the dynamic biotechnology industry.

Biotechnology Industry Overview

Biotechnology encompasses genetic and protein engineering to create medications and therapies for treating and preventing various ailments. Companies within this industry also play a vital role in providing essential components for diagnostics. Given its focus on research and development, the industry continually strives to introduce cutting-edge solutions for healthcare. However, the regulatory approval process, notably by the U.S. Food and Drug Administration (FDA), significantly influences market entries for new discoveries.

Companies like Amgen Inc., Gilead Sciences, Inc., and Celgene Corporation represent the forefront of innovation within this multi-billion-dollar industry, constantly seeking new treatments and medical breakthroughs.

LGVN's Technical Indicators and Earnings Insights

The Relative Strength Index (RSI) indicator for LGVN emerged from oversold territory on October 11, 2023. Such a shift often signifies a potential transition from a downward trend to an upward one. As indicated by AI-generated analysis, in 21 out of 23 similar instances, the stock moved higher after the RSI left oversold territory, suggesting a 90% probability of an upward movement.

However, LGVN's recent earnings report on August 11 reflected earnings per share of -27 cents, slightly missing the estimated -25 cents. With 49.31K shares outstanding, the current market capitalization stands at 46.44M, reflecting a mid-range valuation within the industry.

Market Capitalization and Price Movements in the Biotech Sector

Comparatively, the average market capitalization across the biotechnology industry rests at 2.24B. Ranging from 402M to 434.65B, companies like NVO hold the highest valuation, while PNEXF stands as the lowest valued company in this group.

Notably, LGVN's price action has seen a recent uptick, potentially indicating a positive trend shift. Despite the earnings miss, technical indicators suggest an upward momentum for the stock.

Price Movements and Volume Trends

Analyzing the broader biotech landscape, the average weekly price growth across all stocks in the industry measured 9%. In contrast, the average monthly and quarterly price growths stood at 1% and -16%, respectively. Noteworthy outliers include GYRE, experiencing a significant 1,130% price growth, while KTRA witnessed a notable -89% fall, indicating the considerable volatility within the sector.

Regarding volume, the industry exhibited average weekly, monthly, and quarterly volume growths of 9%, 12%, and 44%, respectively. Such fluctuations indicate the varying degrees of market activity across different time frames.

Summary

AI trading bots, as exemplified by the performance of "Trend Trader, Popular Stocks: Price Action Trading Strategy (TA&FA)," showcased their potential by yielding a notable gain while trading LGVN. The biotechnology industry, characterized by its innovation and regulatory complexities, presents both challenges and opportunities for investors and traders. Despite LGVN's recent earnings miss, the technical indicators suggest a potential positive shift, emphasizing the significance of analyzing both fundamental and technical aspects when making investment decisions within this dynamic sector.

Related Ticker: LGVN

LGVN in upward trend: price rose above 50-day moving average on April 22, 2025

LGVN moved above its 50-day moving average on April 22, 2025 date and that indicates a change from a downward trend to an upward trend. In of 32 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LGVN's RSI Oscillator exited the oversold zone, of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on April 17, 2025. You may want to consider a long position or call options on LGVN as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for LGVN just turned positive on April 21, 2025. Looking at past instances where LGVN's MACD turned positive, the stock continued to rise in of 36 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LGVN advanced for three days, in of 183 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 62 cases where LGVN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 10-day moving average for LGVN crossed bearishly below the 50-day moving average on April 07, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LGVN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.114) is normal, around the industry mean (14.237). P/E Ratio (0.000) is within average values for comparable stocks, (63.881). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.827). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (6.414) is also within normal values, averaging (255.011).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. LGVN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LGVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Sarepta Therapeutics (NASDAQ:SRPT), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.16B. The market cap for tickers in the group ranges from 151 to 275.91B. NONOF holds the highest valuation in this group at 275.91B. The lowest valued company is MYMX at 151.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 7%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was -12%. RLMD experienced the highest price growth at 154%, while VINC experienced the biggest fall at -75%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 14%. For the same stocks of the Industry, the average monthly volume growth was 12% and the average quarterly volume growth was 11%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 70
SMR Rating: 91
Profit Risk Rating: 94
Seasonality Score: -1 (-100 ... +100)
View a ticker or compare two or three
LGVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1951 NW 7th Avenue
Phone
+1 305 909-0840
Employees
25
Web
https://www.longeveron.com
Ad is loading...
Paper wallets are extremely useful tools – beyond being one of the most popular and secure cold storage methods, they make it simple to transfer coins between owners.You can access the funds on your paper wallet by “sweeping” (or importing) them to either a live wallet (like Trezor or Exodus) or an exchange service (like Coinbase). Most services allow you to import them directly from your wallet’s private key, but there are two key exceptions.
"🚀 PHAXIAM Therapeutics SA Skyrockets +18.82%! Dive into this biotech penny stock's stellar week and the industry's broader movements. 📈🔬
Explore annualized returns of +110% for Day Traders and +50% for Swing Traders using Price Action Trading Strategies (TA&FA) on popular managed healthcare stocks like $BIOS $CI $CNC $ELV $HUM $MOH $UNH. Stay updated on the 1-week change of +3% in this dynamic market.
The ethanol industry encompasses a diverse range of business activities, primarily focusing on the production of ethanol and sugar. Beyond these core products, companies within this theme also engage in the development of related assets, such as fuel storage tanks.
Cisco Systems set to soar! 🚀 A.I. predicts +4% growth in the coming month. Is CSCO the next big move in your portfolio? 📈💰
#trading
The Office Equipment/Supplies sector has emerged as a standout performer in recent times, posting an impressive 6.13% increase in its performance over the past week. This surge in performance is supported by a group of tickers, including $ACTG, $SCS, $HNI, $EBF, and $ACCO, which have collectively displayed a positive outlook. In this article, we will delve into the theme of this sector and analyze the group of tickers within it that are driving this positive momentum.
"IBM Skyrockets: +15.54% Quarterly Jump! Dive into the data behind this tech titan's remarkable rally. 📈🚀"
#investment#trading
The pharmaceutical sector is known for its dynamic nature, with companies often experiencing rapid shifts in performance and sentiment. In the past week, pharmaceutical companies, as represented by a group of tickers including RPRX, CALT, INZY, and HRMY, have seen a noteworthy increase in performance, surging by +3.13%. In this article, we will delve into the details of this trend, explore key indicators, and assess the outlook for these companies.
The term 'challenging disorders' envelops a vast expanse of the healthcare sector, extending from medical devices, facilities to biotechs, and pharmaceutical firms.
The ocean transportation sector has been making waves recently, experiencing a significant performance boost of +3.74% over the past week. In this article, we'll delve into the theme and explore the key tickers within this sector, shedding light on their market capitalization, recent price movements, volume trends, and fundamental analysis ratings.
The medical companies segment has experienced a notable increase in performance, recording a weekly gain of +3.53%. This sector encompasses companies involved in the production and supply of pharmaceuticals and essential medical products, catering to a broad spectrum of healthcare needs. Their product offerings include surgical apparel, gloves, hospital furniture, fluid management solutions, and specialized equipment for cosmetic and surgical procedures.
Tickeron launches AI-powered Stock Picker robots to assist hedge fund managers with sector rotation, growth-focused small-cap stocks, and strategic risk management. Using proprietary FLMs, Stock Pickers offer quant-driven signals and adaptive strategies for long-term growth and investment
Tickeron unveils an intuitive AI trading bot interface, offering tailored strategies for day, swing, and trend traders. From beginners to pros, discover tools designed to optimize trading precision, adapt to market volatility, and provide hedge fund-level insights for smarter investments.
#latest#popular#trading
Learn the 27 essential intraday trading rules that every manual trader should master—and discover how Tickeron’s AI platform applies them automatically for consistent, emotion-free execution and smarter, real-time decision-making.
#investment#trading
A $2 trillion sell-off has investors asking: is 2025 the next dot-com crash or a replay of the 2008 recession? This deep dive compares both scenarios, outlines warning signs, and reveals how AI-powered trading strategies can help navigate rising volatility.
#trading#investment
New to trading? Discover 21 powerful lessons every beginner must learn—and see how Tickeron’s AI Double Agent strategies apply them in real time. From mastering risk to managing emotions, this guide helps you trade smarter, safer, and more confidently.
#investment#trading
From the railroads of the 1920s to the AI giants of 2025, market history shows that extreme concentration often precedes massive bubbles and crashes. This article explores five key turning points and how Tickeron’s AI helps traders navigate today’s bubble-prone landscape.
#investment#trading
U.S. tariff tensions rocked markets this week, sending tech stocks into retreat and safe-haven assets like gold and the yen soaring. As investors brace for major earnings and global policy shifts, volatility remains high across equities, currencies, and commodities.
#investment#trading
Tesla’s Q1 2025 earnings could surprise investors as the EV giant looks to rebound from last quarter’s miss. With lowered expectations and increased volatility, Tickeron’s AI-powered strategy helps traders navigate both upside potential and downside risk.
#investment#trading
Gold is on a historic run—up 29% YTD with record-breaking inflows and growing macro tailwinds. Discover why smart investors are eyeing gold, silver, and miners for opportunity, and how AI trading tools are unlocking new ways to profit from the 2025 gold rush.
#investment#trading